Compare BEAM & LFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | LFST |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | 8040 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2019 | 2021 |
| Metric | BEAM | LFST |
|---|---|---|
| Price | $27.72 | $7.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $50.75 | $9.83 |
| AVG Volume (30 Days) | ★ 2.0M | 1.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $24,000.00 | ★ $1,424,285,000.00 |
| Revenue This Year | N/A | $17.18 |
| Revenue Next Year | $33.77 | $14.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 33.33 | 13.85 |
| 52 Week Low | $15.52 | $3.74 |
| 52 Week High | $36.44 | $8.09 |
| Indicator | BEAM | LFST |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 63.92 |
| Support Level | $25.89 | $6.75 |
| Resistance Level | $29.06 | $7.33 |
| Average True Range (ATR) | 1.67 | 0.17 |
| MACD | 0.18 | 0.07 |
| Stochastic Oscillator | 47.35 | 93.08 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.